Sebelipase alfa is a recombinant lysosomal acid lipase used to treat lysosomal acid lipase deficiency. The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs.
- Mechanism
- Curator reviewed · 4 references
Lysosomal acid lipase (LAL) deficiency is an inherited storage disorder caused by a genetic defect that results in a marked decrease or loss in activity of the LAL enzyme. Endogenous LAL is found in the lysosome and is responsible for the breakdown of lipids - a deficiency of these enzymes results in the accumulation of cholesteryl esters and triglycerides, which lead to a number of downstream consequences such as progressive liver disease, malabsorption, and growth failure. Dyslipidemia associated with LAL deficiency may also result in the typical cardiovascular effects associated with elevated lipid levels.
Sebelipase alfa is a recombinant form of human lysosomal acid lipase (rhLAL) which binds to cell surface receptors via glycans expressed on the protein and is subsequently internalized into lysosomes. From within the lysosome, sebelipase alfa catalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides to free cholesterol, glycerol and free fatty acids.
- Primary indication
- Sebelipase alfa is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency.Curator reviewed · 1 structured indication
- Formula / weight
- C1968H2945N507O551S15 · 55000.0 Da
- First approval
- Canada, 2017 · United States, 2015 · European Union, 2020
- Also known as
- SBC-102
- Brand names
Resolves to
What you can answer from here — as of July 07, 2026
Which drugs share a target with Sebelipase alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account